CTRI/2023/02/050043招募中3 期
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2) - B-Well 2
GSK Research & Development Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age: At least 18 years of age at the time of signing the informed consent.
- •Type of Participant and Disease Characteristics:
- •Participants must be HBeAg-negative at screening.
- •Participants who have documented chronic HBV infection more than equal to 6 months prior to Screening AND Currently receiving stable NA therapy defined as no changes to their NA regimen from at least 6 months prior to Screening and with no planned changes to the stable regimen over the duration of the study.
- •Plasma or serum HBsAg concentration >100 IU/mL, but no greater than 3000 IU/mL
- •Plasma or serum HBV DNA concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 IU/mL
- •Alanine aminotransferase (ALT) =2 x ULN
- •Participants who are willing and able to cease their NA treatment in accordance with the protocol.
- •Sex and Contraceptive/Barrier Requirements
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:
- •1 Is a woman of non-childbearing potential (WONCBP) as defined in Section 10.4 OR Is a WOCBP and using a contraceptive method (for a period of 28 days prior to enrollment [first dose of study drug]) that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the study intervention period and for at least 7 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
- •A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention
- •If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- •The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
- •Informed Consent:
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
排除标准
- •Medical Conditions
- •1 Clinically significant abnormalities, aside from chronic HBV infection in medical
- •history (e.g., moderate-severe liver disease other than chronic HBV, acute coronary
- •syndrome within 6 months of screening, major surgery within 3 months of screening,
- •significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis or
- •coagulopathy) or physical examination
- •Co-infection with:
- •a. Current history of Hepatitis C infection or participants that have been cured for
- •<12 months at the time of screening
- •b. Human immunodeficiency virus (HIV)
- •c. Hepatitis D virus
- •3 History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by
- •a. Both APRI >2 and FibroSure/FibroTest result >0.7
- •If only 1 parameter (APRI or FibroSure/FibroTest) result is positive, a
- •discussion with the Medical Monitor is required before inclusion in study is permitted
- •b Regardless of APRI of Fibrosure/FibroTest score, if the participant meets 1 of the
- •following criteria documented from their medical history, they will be excluded
- •from the study
- •Liver biopsy (i.e., Metavir Score F4)
- •Liver stiffness >12 kPa
- •4 Diagnosed or suspected hepatocellular carcinoma as evidenced by the following
- •a. Alpha-fetoprotein concentration =200 ng/mL
- •b. If the screening alpha fetoprotein concentration is =50 ng/mL and <200 ng/mL,
- •the absence of liver mass must be documented by imaging within 6 months before randomization
- •5. History of malignancy within the past 5 years with the exception of specific cancers
- •that are cured by surgical resection (e.g., skin cancer). Participants under evaluation
- •for possible malignancy are not eligible.
- •6. History of vasculitis or presence of symptoms and signs of potential vasculitis
- •(e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without
- •identified cause) or history/presence of other diseases that may be associated with
- •vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis,
- •relapsing polychondritis, mononeuritis multiplex)
- •7. History of extrahepatic disorders possibly related to HBV immune conditions
- •(e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa,
- •cryoglobulinemia, uncontrolled hypertension)
- •8. History of alcohol or drug abuse/dependence
- •a. Current alcohol use as judged by investigator to potentially interfere with
- •participant compliance
- •b. History of or current drug abuse/dependence as judged by the investigator to
- •potentially interfere with participant compliance
- •i. Refers to illicit drugs and substances with abuse potential. Medications
- •that are used by the participant as directed, whether over-the-counter or through prescription, are acceptable and would not meet the exclusion criteria
- •Prior/Concomitant Therapy:
- •9 Currently taking, or took within 3 months of screening, any immunosuppressing
- •drugs (e.g., prednisone), other than a short course of therapy (=2 weeks) or topical/inhaled steroid use.
- •10. Participants to whom immunosuppressive treatment, including therapeutic doses of
- •steroids is contraindicated, should not be considered for enrolment in the study.
- •11. Currently taki
研究者
相似试验
招募中
3 期
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2)JPRN-jRCT2061220074Okawa Yasutoshi900
进行中（未招募）
1 期
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2)Chronic Hepatitis B infectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-002268-53-GRGlaxoSmithKline Research & Development Limited534
招募中
1 期
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis BEUCTR2021-005139-22-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT534
进行中（未招募）
1 期
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis BEUCTR2021-005139-22-FRGlaxoSmithKline Research & Development Limited534
进行中（未招募）
1 期
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis BChronic Hepatitis B infectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-005139-22-HUGlaxoSmithKline Research & Development Limited534